These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 12045315)

  • 21. A randomized, flexible-dose, quasi-naturalistic comparison of quetiapine, risperidone, and olanzapine in the short-term treatment of schizophrenia: the QUERISOLA trial.
    Sacchetti E; Valsecchi P; Parrinello G;
    Schizophr Res; 2008 Jan; 98(1-3):55-65. PubMed ID: 17933497
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Six-month review of weight and metabolic parameters in patients receiving clozapine, risperidone, olanzapine, or quetiapine.
    Kelly DL; Kreyenbuhl J; Love RC; Van-Duong Q; Conley RR
    J Clin Psychiatry; 2003 Sep; 64(9):1133-4. PubMed ID: 14628994
    [No Abstract]   [Full Text] [Related]  

  • 23. Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia.
    Heresco-Levy U; Ermilov M; Shimoni J; Shapira B; Silipo G; Javitt DC
    Am J Psychiatry; 2002 Mar; 159(3):480-2. PubMed ID: 11870017
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Measurement of simple reaction time in antipsychotic treatment of patients with schizophrenia.
    Kores Plesnicar B; Zalar B; Tomori M; Krajnc I
    Wien Klin Wochenschr; 2003 Jan; 115(1-2):58-62. PubMed ID: 12658913
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder.
    Bilder RM; Goldman RS; Volavka J; Czobor P; Hoptman M; Sheitman B; Lindenmayer JP; Citrome L; McEvoy J; Kunz M; Chakos M; Cooper TB; Horowitz TL; Lieberman JA
    Am J Psychiatry; 2002 Jun; 159(6):1018-28. PubMed ID: 12042192
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The impact upon extra-pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia.
    Ritchie CW; Chiu E; Harrigan S; Hall K; Hassett A; Macfarlane S; Mastwyk M; O'Connor DW; Opie J; Ames D
    Int J Geriatr Psychiatry; 2003 May; 18(5):432-40. PubMed ID: 12766921
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative effects of risperidone and olanzapine on cognition in elderly patients with schizophrenia or schizoaffective disorder.
    Harvey PD; Napolitano JA; Mao L; Gharabawi G
    Int J Geriatr Psychiatry; 2003 Sep; 18(9):820-9. PubMed ID: 12949850
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comparative effectiveness study of risperidone and olanzapine in the treatment of schizophrenia.
    Ho BC; Miller D; Nopoulos P; Andreasen NC
    J Clin Psychiatry; 1999 Oct; 60(10):658-63. PubMed ID: 10549681
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Subjective experience and striatal dopamine D(2) receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone.
    de Haan L; Lavalaye J; Linszen D; Dingemans PM; Booij J
    Am J Psychiatry; 2000 Jun; 157(6):1019-20. PubMed ID: 10831489
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Atypical antipsychotic drugs and long-term outcome in schizophrenia.
    Weiden P; Aquila R; Standard J
    J Clin Psychiatry; 1996; 57 Suppl 11():53-60. PubMed ID: 8941171
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients.
    Koro CE; Fedder DO; L'Italien GJ; Weiss S; Magder LS; Kreyenbuhl J; Revicki D; Buchanan RW
    Arch Gen Psychiatry; 2002 Nov; 59(11):1021-6. PubMed ID: 12418935
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The promise of new drugs for schizophrenia treatment.
    Tamminga CA
    Can J Psychiatry; 1997 Apr; 42(3):265-73. PubMed ID: 9114942
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia.
    Gothelf D; Apter A; Reidman J; Brand-Gothelf A; Bloch Y; Gal G; Kikinzon L; Tyano S; Weizman R; Ratzoni G
    J Neural Transm (Vienna); 2003 May; 110(5):545-60. PubMed ID: 12721815
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics.
    Rabinowitz J; Lichtenberg P; Kaplan Z; Mark M; Nahon D; Davidson M
    Am J Psychiatry; 2001 Feb; 158(2):266-9. PubMed ID: 11156809
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comments on "Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders" by Tran and Associates.
    Kasper S; Küfferle B
    J Clin Psychopharmacol; 1998 Aug; 18(4):353-6. PubMed ID: 9690709
    [No Abstract]   [Full Text] [Related]  

  • 36. [Clinical impact of atypical antipsychotics: prospective 6-month study of inpatients treated with risperidone or olanzapine].
    Hamel B; Courtet P; Vergnes C; Boulenger JP
    Therapie; 2001; 56(6):645-52. PubMed ID: 11878086
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of olanzapine and risperidone in schizophrenia: a randomized double-blind crossover design.
    Canive JM; Miller GA; Irwin JG; Moses SN; Thoma RJ; Edgar JC; Sherwood A; Torres F; Lanoue M; Lewis S; Hanlon FM; Weisend MP; Mead V; Tuason VB
    Psychopharmacol Bull; 2006; 39(1):105-16. PubMed ID: 17065975
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Olanzapine for schizophrenia refractory to typical and atypical antipsychotics: an open-label, prospective trial.
    Lindenmayer JP; Volavka J; Lieberman J; Sheitman B; Citrome L; Chakos M; Czobor P; Parker B; Iskander A
    J Clin Psychopharmacol; 2001 Aug; 21(4):448-53. PubMed ID: 11476131
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dopamine D2 receptor occupancy by olanzapine or risperidone in young patients with schizophrenia.
    Lavalaye J; Linszen DH; Booij J; Reneman L; Gersons BP; van Royen EA
    Psychiatry Res; 1999 Nov; 92(1):33-44. PubMed ID: 10688158
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Obsessive-compulsive symptoms in schizophrenia: a comparison of olanzapine and placebo.
    Baker RW; Ames D; Umbricht DS; Chengappa KN; Schooler NR
    Psychopharmacol Bull; 1996; 32(1):89-93. PubMed ID: 8927681
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.